EFFECTIVE LONG-TERM TREATMENT OF ACROMEGALY WITH A LONG-ACTING SOMATOSTATIN ANALOGUE (SMS 201–995)

Abstract

Nine acromegalic patients, six previously untreated, were studied before and after 3–15 months of treatment with a long‐acting somatostatin analogue (SMS 201–995; 100 μg injected s.c. three times daily). During treatment, the mean (± SEM) 24‐h GH concentration fell from 82 ± 22 mIU/1 to 33 ± 7 mIU/1 (P < 0.001), and eight of the 9 patients showed a reduction of at least 50% in GH levels in the fasting state and/or during a glucose tolerance test. There was a significant 30% fall in serum concentrations of insulin‐like growth factor (IGF‐1) with SMS. All patients showed rapid clinical improvement, with diminished sweating and headaches, and reduction in skinfold thickness, hand volumes and finger size. Computer tomographic scanning of the pituitary in eight patients showed no change in the size of the pituitary tumour during treatment. The only side‐effects of SMS noted were transient abdominal discomfort and loose stools in two patients on initiating therapy. Although fasting plasma glucose concentration did not change during treatment (5.4 ± 0.3 vs 5.5 ± 0.3 mmol/l), mean 24‐h plasma glucose concentration was higher with SMS (6.6 ± 0.5 mmol/l vs 6.0 ± 0.4 mmol/l; P < 0.02). Mean 24‐h plasma insulin concentration fell from 87 ± 11 mIU/1 before treatment to 39 ± 6 mIU/1 during treatment (P < 0005). No change in other anterior pituitary hormones was observed. SMS appears to be a safe, rapidly effective, long‐term treatment for certain patients with acromegaly.